TARGETING RAS SYMPOSIUM

For decades, RAS oncogenes were considered undruggable, a challenge that seemed overwhelming. However, groundbreaking basic science discoveries eventually dismantled this long-held belief, opening the door to the development of KRAS-specific inhibitors. These pivotal advancements have led to the approval of the first RAS-targeted therapies in recent years, marking a significant milestone in cancer treatment. Since then, an explosion of novel compounds, utilizing distinct mechanisms of action, has brought about a new era of targeted cancer therapies. These advancements not only offer promising novel therapeutic options but also create opportunities to address longstanding biological questions that have troubled the field.

The rapid progress in the RAS research landscape and the evolution of therapeutic strategies demand an ongoing, dynamic exchange of ideas. Now more than ever, it is crucial to foster dialogue among basic researchers, clinicians, industry experts, and patients. Reflecting on the success of our inaugural Targeting RAS meeting in 2023, we are excited to continue this conversation.

We warmly invite you to join us once again in Salamanca, Spain, this October 2025 for the second edition of Targeting RAS: New Avenues and Challenges. This symposium will bring together leaders from across the scientific community to explore the latest advancements and the challenges that lie ahead in the RAS field.